首页> Cancer biology & therapy> Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.

导出 OA

翻译打印收藏纠错

第一作者： Brajesh P,Kaistha

第一单位： Oncology R & D, AstraZeneca, Cambridge, UK.

作者： Brajesh P,Kaistha ^[1] ; Gozde,Kar ^[1] ; Andreas,Dannhorn ^[2] ; Amanda,Watkins ^[1] ; Grace,Opoku-Ansah ^[1] ; Kristina,Ilieva ^[3] ; Stefanie,Mullins ^[4] ; Judith,Anderton ^[1] ; Elena,Galvani ^[1] ; Fabien,Garcon ^[1] ; Jean-Martin,Lapointe ^[5] ; Lee,Brown ^[2] ; James,Hair ^[1] ; Tim,Slidel ^[1] ; Nadia,Luheshi ^[1] ; Kelli,Ryan ^[1] ; Elizabeth,Hardaker ^[1] ; Simon,Dovedi ^[1] ; Rakesh,Kumar ^[6] ; Robert W,Wilkinson ^[1] ; Scott A,Hammond ^[6] ; Jim,Eyles ^[1]

作者单位： Oncology R & D, AstraZeneca, Cambridge, UK. ^[1] Imaging Sciences, AstraZeneca, Cambridge, UK. ^[2] Oncology R & D, AstraZeneca, Cambridge, UK.;Immunooncology, MorphoSys AG, Planegg, Germany. ^[3] Oncology R & D, AstraZeneca, Cambridge, UK.;Translational Science, F-Star, Cambridge, UK. ^[4] Oncology Safety Pathology, AstraZeneca, Cambridge, UK. ^[5] Oncology R & D, AstraZeneca, Gaithersburg, MD, USA. ^[6]

关键词 Anti-CD73 Oleclumab adenosine bulk RNA-sequencing (RNAseq)chemotherapy immune-checkpoint blockade (ICB)immunotherapy radiotherapy syngeneic tumor models tumor microenvironment (TME)